Stock Events

Cantargia AB 

SEK4.99
4
+SEK0.1+2.13% Friday 15:29

Statistics

Day High
5.08
Day Low
4.8
52W High
6.08
52W Low
2.56
Volume
412,566
Avg. Volume
577,343
Mkt Cap
851.94M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

21MayExpected
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q3 2023
Q4 2023
Q1 2024
-0.77
-0.67
-0.57
-0.47
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CANTA.ST. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Cantargia AB (publ), a biotechnology company, develops antibody-based treatments for life threatening diseases. The company is developing CAN04 (nadunolimab), an interleukin-1 receptor accessory protein (IL1RAP) binding antibody, which is in Phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in preclinical phase for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops CANxx, an IL1RAP-based antibody platform. The company has collaboration agreements with Patheon Biologics B.V. and BioWa Inc. for the manufacture and production of CAN04; and GEICAM, Spanish breast cancer group. Cantargia AB (publ) was incorporated in 2009 and is based in Lund, Sweden.
Show more...
CEO
Mr. Goran Forsberg
Employees
22
Country
SE
ISIN
SE0006371126
WKN
000A2JAZX

Listings